Fig. 3: Kaplan-Meier estimates for PET-2-negative and PET-2-positive patients assigned to receive combined-modality treatment.
From: Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma
A Progression-free survival, DS 1–2 vs DS ≥ 3. B Overall survival, DS 1–2 vs DS ≥ 3. C Progression-free survival, DS 1–3 vs DS ≥ 4. D Overall survival, DS 1–3 vs DS ≥ 4. Abbreviations: PET-2 positron emission tomography after two cycles of chemotherapy, PFS progression-free survival, DS, Deauville score. *Cox model adjusted for stratification factors age, sex, B symptoms, disease localization (supra- vs. infra diaphragmatic), albumin level (<4 g/dL vs. ≥4 g/dL), and bulky disease.
